OPQ touts progress on quality management maturity, KASA in annual report
The US Food and Drug Administration’s (FDA) Office of Pharmaceutical Quality (OPQ) reported that progress has been made over the past year in advancing its quality management maturity initiative and in its quality assessment review process in its 2022 annual report.
The agency addressed some of the progress that has been made in its quality management maturity (QMM) initiative, which aims to measure the strength of facilities’ quality practices. FDA said it concluded two QMM pilots in February 2022 to develop such benchmarks for domestic finished dosage form manufacturers and international active pharmaceutical ingredient manufacturers.
OPQ subsequently published a white paper in April describing the need and considerations for a QMM program and potential impacts on stakeholders. (RELATED: FDA proposes to rate pharmaceutical manufacturing facilities, Regulatory Focus 7 April 2022)
The report also said that progress has been made in the Knowledge-aided Assessment and Structured Applications (KASA) program to improve and modernize the quality assessment of drug applications.
In 2022, OPQ added 16 new analytic features to KASA and used the KASA template to assess over 500 generic drug applications. In November 2022, an FDA Advisory Committee voted unanimously to further expand KASA to assessing new drug and biologics applications.
The report also notes that the agency continued to rely on alternative tools, such as requesting information from a facility in lieu of an inspection in 2022, as the COVID-19 public health emergency limited its ability to conduct facility inspections. In 2022, OPQ staff conducted 65 pre-license facility inspections in 18 countries and 10 states and used remote regulatory assessments to act on 85 regulatory submissions. The report stated that “while inspection remains the gold standard, FDA will continue to use remote regulatory assessments to augment inspection activities.
In other areas, OPQ highlighted its role in engaging with other international regulators to “coordinate regulatory strategies and develop shared regulatory practices.” OPQ is a participant in two pilot programs with the International Coalition of Medicines Regulatory Authorities (ICMRA) on hybrid inspections and collaborative assessments of post-approval changes. These pilots aim to develop a common framework for international facility assessments and assessing quality-related postapproval changes.
OPQ also approved four submissions that included established conditions in 2022, following the release of the International Council for Harmonisation’s (ICH) Q12 guideline the previous year. The Q12 guideline supports the addition of established conditions to ease the process for implementing postapproval changes. (RELATED: FDA issues ICH Q12 guidance and others on clinical trials, safety testing and biowaivers, Regulatory Focus 11 May 2021)
BARCELONA – A panel of experts at the RAPS AI in Regulatory Conference discussed how artificial intelligence (AI) is being used by a wide range of stakeholders, including notified bodies and healthcare product manufacturers.
Australia’s Therapeutic Goods Administration (TGA) is considering adding unique device identification (UDI) information to certificates of free sale for medical devices.